Stryker (NYSE:SYK) had its target price hoisted by stock analysts at UBS Group from $202.00 to $215.00 in a report issued on Friday, BenzingaRatingsTable reports. The brokerage currently has a “neutral” rating on the medical technology company’s stock. UBS Group’s price objective indicates a potential upside of 11.23% from the stock’s previous close.
SYK has been the topic of several other research reports. Oppenheimer reissued a “hold” rating and set a $215.00 target price on shares of Stryker in a research report on Friday. Cowen cut their target price on Stryker from $240.00 to $220.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. Citigroup raised their target price on Stryker from $227.00 to $232.00 and gave the stock a “buy” rating in a research report on Friday. Zacks Investment Research downgraded Stryker from a “hold” rating to a “sell” rating and set a $190.00 target price on the stock. in a research note on Monday, May 4th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Stryker from $240.00 to $210.00 and set an “overweight” rating for the company in a research report on Wednesday, April 15th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Stryker presently has a consensus rating of “Buy” and an average price target of $216.25.
Shares of NYSE SYK opened at $193.30 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.77 and a current ratio of 2.58. Stryker has a fifty-two week low of $124.54 and a fifty-two week high of $226.30. The firm has a market capitalization of $75.04 billion, a PE ratio of 45.91, a price-to-earnings-growth ratio of 3.48 and a beta of 0.84. The stock’s 50-day simple moving average is $186.61 and its 200-day simple moving average is $189.31.
Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. Stryker had a return on equity of 20.53% and a net margin of 11.38%. The business had revenue of $2.76 billion for the quarter, compared to analyst estimates of $2.63 billion. On average, sell-side analysts forecast that Stryker will post 6.25 earnings per share for the current fiscal year.
In other news, Director Srikant M. Datar sold 200 shares of Stryker stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $186.01, for a total transaction of $37,202.00. Following the sale, the director now owns 17,686 shares of the company’s stock, valued at approximately $3,289,772.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Katherine Ann Owen sold 9,149 shares of Stryker stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $186.79, for a total value of $1,708,941.71. Following the sale, the vice president now directly owns 1,085 shares in the company, valued at approximately $202,667.15. The disclosure for this sale can be found here. Insiders have sold 30,670 shares of company stock worth $5,775,251 over the last 90 days. Corporate insiders own 6.80% of the company’s stock.
Several large investors have recently made changes to their positions in the company. State Street Corp grew its holdings in shares of Stryker by 1.0% during the 1st quarter. State Street Corp now owns 13,812,677 shares of the medical technology company’s stock worth $2,307,526,000 after purchasing an additional 136,388 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Stryker by 0.4% during the 1st quarter. Bank of New York Mellon Corp now owns 7,006,593 shares of the medical technology company’s stock worth $1,166,528,000 after purchasing an additional 28,171 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Stryker by 20.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,216,034 shares of the medical technology company’s stock worth $1,034,908,000 after purchasing an additional 1,069,721 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Stryker by 19.5% during the 1st quarter. Wells Fargo & Company MN now owns 2,619,970 shares of the medical technology company’s stock worth $436,199,000 after purchasing an additional 427,056 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Stryker by 2.9% during the 1st quarter. Legal & General Group Plc now owns 2,254,331 shares of the medical technology company’s stock worth $375,668,000 after purchasing an additional 64,514 shares in the last quarter. 71.24% of the stock is currently owned by institutional investors.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: Determine Your Level of Risk Tolerance
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.